Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial.

By M. Henke, R. Laszig, C. Rübe, U. Schäfer, K. Haase, B. Schilcher, S. Mose, K. Beer, Ulrich Burger, C. Dougherty and 1 more. The Lancet, 2003

1,259 citations recorded by the source corpus.

Subfields: Biochemistry, Hematology, Radiology, Nuclear Medicine and Imaging

View Paper: https://www.semanticscholar.org/paper/7604f27f551a893fd642fa6e348911b87c292ba2

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. C. Bokemeyer
2. P. Barrett-Lee
3. J. Nortier
4. H. Ludwig
5. P. Kosmidis
6. P. Olmi
7. D. Schrijvers
8. P. Gascón

Citations in the corpus

• The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. (2004, background): “One study was terminated early because of observed higher early mortality in the epoetin- treated group [21] and the other revealed better outcome in the placebo patients [22].”
• Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. (2008, neutral): “97 Witzig et al,57 2005 9/168 (5) 6/165 (4) 3.”